BOUNDLESS BIO INC
BOLDNASDAQTrading Snapshot
- Day Range
- $2.81 – $2.88
- 52-Week Range
- $0.96 – $2.97
- Volume
- $4.34B
- Avg Volume
- $3.57B
- Shares Outstanding
- 22.5M
- Next Earnings
- Sep 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $11M
- Last Q Revenue
- $3M
- P/E Ratio
- -1.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.85
- Dividend Yield
- 0.00%
Why Investors Own BOLD
- ✓High-growth profile — revenue up +4.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 37% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BOUNDLESS BIO INC
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.